TLRY

Zacks.com users have recently been watching Tilray Brands (TLRY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Consolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost Savings Higher Cultivation Yields and Expected Reestablishment of EU-GMP Certification Strengthen Tilray's Canadian Cannabis Platform and Position the Business for Continued Growth in Canada, International Markets, and Future U.S. Medical Cannabis Markets When Permissible Tilray Raises Fiscal 2027 Adjusted EBITDA Guidance to $70 Million–$75 Million, Increasing the Lower End of the Range NEW YORK and LONDON and LEAMINGTON, Ontario, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today announced plans to consolidate its Canadian cannabis operations, transitioning cultivation and pre-roll production from its Foss facility in Fenwick, Ontario to its Masson, Quebec and Cayuga, Ontario facilities. This strategic initiative is expected to generate approximately US$10 million in annualized cost savings by the end of fiscal 2028.

Tilray Brands has shifted from a marijuana company to a global brand manager across marijuana, beverages, and wellness. The company's fiscal first quarter 2027 earnings highlight just how much the business has changed.

Canopy Growth (CGC -4.34%) primarily generates revenue by selling medical and recreational cannabis products to consumers across several international regions.

Successfully Completed Consolidation of U.S. Brewing Footprint from 10 Facilities to Six Identifying Further Opportunities to Reduce Complexity, Improve Brewery Utilization and Strengthen Margins Transformation Initiatives Strengthen Operational Footprint Ahead of the Carlsberg U.S. Partnership Launching January 1, 2027; Targeting One Million Cases in First-Year Sales Through Tilray's Existing Production and Distribution Infrastructure Reaffirms Fiscal 2027 Adjusted EBITDA Guidance of $68 million to $75 million NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today announced additional initiatives across its U.S. beverage business, designed to reduce complexity and increase operational efficiency, targeting approximately $20 million in annualized cost savings by the end of fiscal 2028. Having now consolidated its U.S. brewing footprint from 10 facilities to six, Tilray is well-positioned to enter the next phase of transformation of its U.S. beverage business, pursuing additional opportunities across manufacturing, warehousing, procurement and logistics to lower production costs and increase utilization at its remaining breweries.

Tilray's low valuation may be enticing to investors as its market cap is just $400 million. The business, however, struggles to grow organically on a consistent basis.

ELLON, Scotland and LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- BrewDog , a leader in U.K. craft beer and one of the world's most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), and West Ham United Football Club today unveiled Boleyn Brew, a first-of-its-kind fan-created beer built with West Ham supporters and brewed for matchday. From flavour and style to storytelling, branding and name, Hammers helped shape every part of the beer.

Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West

CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal's National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical's EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.

Tilray reported Q1-2027 financial results last week with increasing revenue from its BrewDog operations; Cannabis revenue decreased. The company expects its new beer assets along with its international cannabis operations to continue to drive growth. The company reported a net loss and negative free cash flow.